These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 38745129

  • 1. An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome.
    Fung WW, Chao AC, Pang WF, Wong RS, Chow KM, Szeto CC.
    BMC Nephrol; 2024 May 14; 25(1):164. PubMed ID: 38745129
    [Abstract] [Full Text] [Related]

  • 2. Biallelic mutations in the CFHR genes underlying atypical hemolytic uremic syndrome in a patient with catastrophic adult-onset Still's disease and recurrent macrophage activation syndrome: A case report.
    Dillemans L, Bekhuis Y, Betrains A, Yu K, van Hemelen M, Pörtner N, De Somer L, Matthys P, Breckpot J, Tousseyn T, Peetermans M, Proost P, Wouters C, Vanderschueren S.
    Clin Immunol; 2023 Dec 14; 257():109815. PubMed ID: 37898413
    [Abstract] [Full Text] [Related]

  • 3.
    Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Noris M, Bresin E, Mele C, Remuzzi G.
    ; 1993 Dec 14. PubMed ID: 20301541
    [Abstract] [Full Text] [Related]

  • 4. Adult-onset Still's disease with concurrent thrombotic microangiopathy: Observations from pooled analysis for an uncommon finding.
    Ananthaneni A, Shimkus G, Weis F, Adu-Dapaah E, Lakra R, Ramadas P, Hayat S.
    Eur J Haematol; 2024 Apr 14; 112(4):484-492. PubMed ID: 37997494
    [Abstract] [Full Text] [Related]

  • 5. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD.
    Nephrology (Carlton); 2018 Jun 14; 23(6):507-517. PubMed ID: 29419916
    [Abstract] [Full Text] [Related]

  • 6. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
    Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T, German-Austrian HUS Study Group.
    Clin J Am Soc Nephrol; 2013 Mar 14; 8(3):407-15. PubMed ID: 23243267
    [Abstract] [Full Text] [Related]

  • 7. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C, Delmas Y, Roumenina LT, Contin-Bordes C, Lepreux S, Bridoux F, Goujon JM, Bachelet T, Touchard G, Frémeaux-Bacchi V, Combe C.
    Am J Kidney Dis; 2015 Aug 14; 66(2):331-6. PubMed ID: 26015278
    [Abstract] [Full Text] [Related]

  • 8. [Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].
    Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.
    Rev Med Interne; 2011 Apr 14; 32(4):232-40. PubMed ID: 21376430
    [Abstract] [Full Text] [Related]

  • 9. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D, Yu XJ, Wang FM, Xu BN, He YD, Chen Q, Wang SX, Yu F, Song WC, Zhao MH.
    Am J Reprod Immunol; 2015 Oct 14; 74(4):345-56. PubMed ID: 26011580
    [Abstract] [Full Text] [Related]

  • 10. CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome.
    Piras R, Valoti E, Alberti M, Bresin E, Mele C, Breno M, Liguori L, Donadelli R, Rigoldi M, Benigni A, Remuzzi G, Noris M.
    Front Immunol; 2022 Oct 14; 13():1011580. PubMed ID: 36793547
    [Abstract] [Full Text] [Related]

  • 11. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.
    Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R.
    Ther Apher Dial; 2018 Apr 14; 22(2):178-188. PubMed ID: 29250893
    [Abstract] [Full Text] [Related]

  • 12. Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report.
    Kurihara S, Yamaguchi A, Sonoda K, Yamada Y, Harada M, Hashimoto K, Shimojo H, Ikeda Y, Kamijo Y.
    BMC Nephrol; 2024 Jul 15; 25(1):224. PubMed ID: 39009967
    [Abstract] [Full Text] [Related]

  • 13. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function.
    Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M.
    Br J Haematol; 2020 Apr 15; 189(1):182-186. PubMed ID: 31879952
    [Abstract] [Full Text] [Related]

  • 14. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG, Kirsztajn GM.
    J Bras Nefrol; 2010 Apr 15; 32(3):303-15. PubMed ID: 21103695
    [Abstract] [Full Text] [Related]

  • 15. Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab.
    Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-Gvili A.
    Ren Fail; 2014 Aug 15; 36(7):1119-21. PubMed ID: 24828571
    [Abstract] [Full Text] [Related]

  • 16. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.
    Hofer J, Giner T, Józsi M.
    Semin Thromb Hemost; 2014 Jun 15; 40(4):431-43. PubMed ID: 24799303
    [Abstract] [Full Text] [Related]

  • 17. Rescued from desperation: adult-onset Still's disease with life-threatening interstitial lung disease and macrophage activation : Successful treatment by Tocilizumab.
    Zhang G, Liu W, Zhang X, Liu L.
    Z Rheumatol; 2022 May 15; 81(4):335-338. PubMed ID: 34378080
    [Abstract] [Full Text] [Related]

  • 18. Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.
    Åkesson A, Blom AM, Klintman J, Zetterberg E.
    Nephrology (Carlton); 2017 Jul 15; 22(7):555-561. PubMed ID: 27175932
    [Abstract] [Full Text] [Related]

  • 19. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.
    Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M.
    Nephrol Dial Transplant; 2010 Jan 15; 25(1):136-44. PubMed ID: 19666655
    [Abstract] [Full Text] [Related]

  • 20. Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult-onset Still's disease receiving interleukin-6 inhibitor treatment.
    Naniwa T, Yamabe T, Ohmura SI, Uehara K, Tamechika SY, Maeda S, Isogai S, Wada J.
    Int J Rheum Dis; 2022 Sep 15; 25(9):1003-1012. PubMed ID: 35719030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.